Comment on Prognostic value of tumor thickness in patients with Merkel cell carcinoma J Surg Oncol. 2007 Jun 15;95(8):614-5.
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer
